Toronto-based RetiSpec aims to bring Alzheimer’s screening to optometrists by the end of next year. The company, backed by USD $10 million in new funding, uses retinal imaging technology to detect early signs of Alzheimer’s disease, leveraging an AI algorithm to analyze retinal scans.
RetiSpec’s approach offers a less invasive alternative to PET scans and spinal taps, making Alzheimer’s diagnosis more accessible. The funding round, led by iGan Partners and supported by Eli Lilly and Topcon Healthcare, will help the company scale up and work with regulators. RetiSpec is also exploring applications for Parkinson’s disease.
Want to know more? Check out the source code on The Logic.